On the Rag 4-Times a Year?
Yup!  Now it IS Possible!

(& Gentlemen, that equates to 66% fewer opportunities for an 'Oops!")

LA JOLLA, CA: 09/09/2003 -- On September 11th, the Association of Reproductive Health Professionals' (ARHP) will sponsor a timely presentation on extended regimen contraception -- the management of menstrual cycles by skipping the hormone free week in a birth control pill. The FDA approved the first extended regimen contraceptive, marketed under the name Seasonale, on September 5th. ARHP will also be releasing preliminary data from a national survey entitled Women's Attitudes, Beliefs, and Perceptions About Menstrual Periods, which features new insights into women's acceptance and experience with menstruation.

"Extended regimen contraceptives give women another reproductive health choice-when and whether to experience menstrual bleeding," says Andrew M. Kaunitz, MD, who will be conducting the session and is a professor and assistant chairman of obstetrics and gynecology at the University of Florida, Health Science Center in Jacksonville. "For years clinicians on an individualized basis have safely and effectively prescribed oral contraceptives in such a way as to reduce the frequency of menstrual cycles. The convenience of the first pill FDA-approved for extended use (Seasonale) will increase acceptance of this option."
Barr Laboratories, Inc. (NYSE:BRL) September 8, 2003 announced that the U.S. Food and Drug Administration (FDA) has approved the Company's SEASONALE(R) (levonorgestrel and ethinyl estradiol) 0.15 mg/0.03 mg tablets, an extended-cycle oral contraceptive for the prevention of pregnancy. SEASONALE, the first and only FDA-approved extended-cycle oral contraceptive, will be available by prescription to women at the end of October 2003. 

The SEASONALE regimen is designed to reduce the number of periods from 13 to 4 per year. SEASONALE is a 91-day regimen taken daily as 84 active tablets of 0.15 mg of levonorgestrel/0.03 mg of ethinyl estradiol, followed by 7 inactive tablets. By contrast, oral contraceptive products currently available in the United States are based on a 28-day regimen.

"The SEASONALE approval represents several 'firsts' for Barr. It is our first internally developed New Drug Application (NDA) product to gain FDA approval and we believe that it represents a significant advance in oral contraception," said Bruce L. Downey, Barr's Chairman and CEO. 

"The development of our SEASONALE product underscores Barr's commitment to women's health care, especially in the area of oral contraception. It is the first of what we believe will be several additional new drug applications for women's healthcare products over the next several years." SEASONALE was developed by Barr under an agreement with Eastern Virginia Medical School (EVMS)."With today's approval of SEASONALE, women have a new choice when deciding on oral contraception," said Carole S. Ben-Maimon, M.D., President and COO of Barr Research. "For those women who prefer the convenience of fewer periods, SEASONALE offers a safe and effective alternative to the traditional 28-day oral contraceptive regimen." 

The Company's 250-person Duramed Pharmaceuticals, Inc. women's healthcare sales force will promote the SEASONALE oral contraceptive directly to physicians and healthcare providers. Duramed is a wholly owned subsidiary of Barr Laboratories, Inc., resulting from the 2001 merger of Barr and Duramed. The Duramed sales force currently promotes Cenestin(R) (Synthetic Conjugated Estrogens, A).

Clinical Data

The clinical data supporting FDA approval of the SEASONALE(R) (levonorgestrel and ethinyl estradiol) 0.15 mg/0.03 mg tablets product resulted from a randomized, open-label, multi-center trial that ended in March 2002 and an extension to that trial. In the trials, SEASONALE was found to prevent pregnancy and had a comparable safety profile to a more traditional oral contraceptive.

In the trial, the most reported adverse events were nasopharyngitis, headache and intermenstrual bleeding or spotting.

SEASONALE has been formulated using well-established components, long recognized as safe and effective when used in a 28-day regimen. SEASONALE offers 4 periods per year as compared to 13 per year with traditional oral contraceptives. When prescribing SEASONALE, the convenience of fewer planned menses (4 per year instead of 13 per year) should be weighed against the inconvenience of increased intermenstrual bleeding and/or spotting. A recently published Roper study found that when given the choice, nearly two-thirds of women would be interested in reducing their number of periods to 4 times per year (1).

Important Information About Oral Contraceptives

It is estimated that more than 16 million women currently take oral contraceptives in the United States. Oral contraceptives are not for every woman. Serious risks associated with birth control pills that can be life threatening include blood clots, stroke and heart attack. These risks are increased in women who smoke cigarettes, especially women over 35. Women who use oral contraceptives should not smoke. Some women should not use birth control pills, including women who have had a heart attack, stroke, blood clots, certain cancers or liver diseases, unexplained vaginal bleeding, and those who are or may be pregnant. Birth control pills do not protect against HIV infection (AIDS) or other sexually transmitted diseases. Use of SEASONALE provides women with more hormonal exposure on a yearly basis than conventional monthly oral contraceptives containing similar strength synthetic estrogens and progestins (an additional 9 weeks per year). While this added exposure may pose an additional risk of thrombotic and thromboembolic disease, studies to date with SEASONALE have not suggested an increased risk of these disorders. Barr Laboratories, Inc. is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals.

Safe Harbor Statement:

To the extent that any statements made in this report contain information that is not historical, these statements are essentially forward-looking. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include: the difficulty in predicting the timing and outcome of legal proceedings, including those relating to patent challenge settlements and patent infringement cases; the difficulty of predicting the timing of U.S. Food and Drug Administration, or FDA, approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods past initial patent terms; market and customer acceptance and demand for our pharmaceutical products; reimbursement policies of third party payors; our ability to market our proprietary products; the successful integration of acquired businesses and products into our operations; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing; the ability to develop and launch new products on a timely basis; the availability of raw materials; availability of any product we purchase and sell as a distributor; the regulatory environment; fluctuations in operating results, including spending for research and development, sales and marketing and patent challenge activities; the outcome of the litigation between Wyeth and Natural Biologics, and our resulting ability to have access to the principal raw material for our conjugated estrogens product produced by Natural Biologics and have our loans to Natural Biologics repaid in full; and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission, or SEC. Forward looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements.

Relationship and support group